Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells

Ahdab AlsaieediInstitute of Immunity and Transplantation, UCL Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK;Faculity of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

Angelika HollerInstitute of Immunity and Transplantation, UCL Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK

Pedro VelicaInstitute of Immunity and Transplantation, UCL Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK

Gavin BendleDivision of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Hans J. StaussInstitute of Immunity and Transplantation, UCL Division of Infection and Immunity, University College London, Royal Free Hospital, London, UKCorrespondence[email protected]

Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date